MORPHOLOGY AND CELL IMAGING CORE

形态和细胞成像核心一直在提供专业知识、技术支持和 帮助形态和成像方法以及最先进的设备 在博士的领导下，向DDRCC成员提供了超过18年的复杂成像技术。 斯特尼尼。核心所提供的服务对阐明 在胃肠道控制中起作用的信号分子的组织和细胞分布 (GL)的功能和在G1紊乱的发病机制中的作用，以及可视化信号通路 调节细胞功能。受益于核心的研究使 我们对神经元和激素通路之间功能相互作用的理解进展 规范Gl的职能，并已出版了许多出版物，并进行了长期的合作。 多年来，为了反映需求，在服务方面进行了几次添加和更新 以及形态和成像技术的演变，其目标是 提升核心能力。形态能力的增强包括1) 增加老鼠病理服务和2)成立Well中央银行 具有特征的抗体。在我们之前的竞争中增加了小鼠病理服务 更新以应对日益增长的许多治疗需求：DDRCC调查人员的专业知识和 协助确定可在遗传学上检测到的表型异常或病理 被越来越多地用于治疗的操纵小鼠：DDRCC。Nora Rozengurt博士，经验丰富的 在自然和实验诱导的小鼠病理学方面拥有丰富专业知识的兽医病理学家 一直担任核心副主任监督这项服务，这项服务已被广泛使用 在过去的资助周期中。增加了抗体中央银行，以提供集中的 用于在前几个资助期内治愈时产生的大量抗体的系统 以及被许多研究人员用作特定细胞类型或标记的其他抗体 细胞内信号分子。中央银行的可用性具有良好的特点和 有效的感兴趣的抗体治愈：DDRCC调查人员是一个强大的资源，将允许 CURE的有效途径：DDRCC调查人员可以通过 形态与细胞成像核心。戈登·奥宁博士将作为副主任加入核心集团 负责维护中央银行的抗体。 我们的成像服务能力有了显著增强，包括1) 增加了高度精密的设备和2)采用了新的成像技术， 将进一步提高我们在细胞和亚细胞水平和变化中可视化分子的能力 在细胞激活后的第二信使系统中。我们影像的一大丰富 设施已经增加了最先进的共焦显微镜，蔡司LSM 510Meta 配备复杂的软件(如去卷积、图像分析、3-D渲染) 活的和固定的细胞成像。这个系统是在机构资金的帮助下从 大卫·格芬加州大学洛杉矶分校医学院，就在前一次竞争更新之前，从那时起 已经被越来越多的治愈药物大量使用：DDRCC调查人员。在过去 在投资周期中，我们还通过收购蔡司来增强我们的钙成像仪器 配备短波长(405 Nm)和可见光激光的帕斯卡共焦显微镜 激动人心。全细胞膜片钳记录装置可用于执行单个细胞 电生理学与共聚焦活细胞成像同步进行。这个显微镜，它也有 在机构资金的帮助下从医学院院长办公室获得，位于 加州大学洛杉矶分校与蔡司510元共焦在同一栋建筑内，已被多家公司广泛使用 DDRCC调查人员。我们的服务也通过添加新的映像进行了升级 活细胞中的技术，包括量子点(Q点)、可光激活蛋白质和 用荧光标签标记的第二信使生物传感器。这些重大改进将 进一步提高我们在细胞和亚细胞水平上可视化大分子的能力 第二信使系统在细胞激活后的变化。奥斯瓦尔多·雷伊博士将加入CORE 作为核心联席总监的人员，负责监督建议涵盖的新成像方法 许多发改委调查人员的新需求。 最后，将增加对可用于治愈的共享资源的使用：DDRCC 调查人员通过核心主任和加州大学洛杉矶分校现有核心所做的安排，这些安排是 由病理和实验医学系、脑研究所和 纳米技术研究所。这些相互作用将继续是形态学和 细胞成像核心，以增强核心的技术能力，并确保最佳利用 加州大学洛杉矶分校社区内的共享资源，包括CURE：DDRCC社区。 总体而言，上面简要概述并在正文后面更详细地解释了服务的添加 应用情况的变化反映了发改委研究兴趣和重点的演变，以及 形态和成像技术。这些新增功能将提供最先进的方法和 多种设备治愈：对阐明基本正常感兴趣的DDRCC调查人员 或不同类型细胞控制消化功能的异常机制。

The Morphology and Cell Imaging Core has been providing expertise, technical support and assistance for morphological and imaging approaches as well as state-of-the-art equipment for sophisticated imaging techniques to the DDRCC members for over 18 years under the leadership of Dr. Sternini. The services provided by the core have been instrumental for studies that have elucidated the tissue and cellular distribution of signaling molecules that play a role in the control of gastrointestinal (Gl) function and in the pathogenesis of Gl disorders as well as for visualizing signaling pathways that regulate cellular functions. The studies that have benefited from the core have made important advances in our understanding of functional interactions between neuronal and hormonal pathways regulating Gl functions and have resulted in many publications and in long-lasting collaborations. There have been several additions and updates in services throughout the years to reflect the needs of DDRCC members and the evolving of morphological and imaging technologies, with the goal of enhancing the Core capabilities. Enhancement of morphological capabilities includes 1) the addition of mouse pathology services and 2) the incorporation of a Central Bank of well characterized antibodies. The mouse pathology services have been added in our previous competitive renewal in response to the increasing need of many CURE: DDRCC investigators for expertise and assistance in defining phenotypical abnormalities or pathologies that can be detected in genetically manipulated mice, which are increasingly used at CURE:DDRCC. Dr. Nora Rozengurt, an experienced veterinary pathologist with extensive expertise in natural and experimentally induced mouse pathology has been serving as Core Associate Director to supervise this service, which has been extensively used during the past funded cycle. The antibodies central bank has been added to provide a centralized system for the wealth of antibodies that have been produced at CURE during previous funding periods and for other antibodies that are used by many investigators as markers for specific cell types or intracellular signaling molecules. The availability of a centralized bank of well characterized and validated antibodies of interest to CURE: DDRCC investigators is a powerful resource that will allow an effective access of CURE:DDRCC investigators to a variety of reagents that can be utilized through the Morphology and Cell Imaging Core. Dr. Gordon Ohning will join the Core as Associate Director to be in charge of the maintenance of the Central Bank of antibodies. There has been a significant enhancement of the capabilities of our imaging services, including 1) the addition of highly sophisticated equipment and 2) the incorporation of new imaging technologies that will further advance our ability to visualize molecules at the cellular and subcellular levels and changes in second messenger systems following cellular activation. A major enrichment of our imaging facilities has been the addition of a state-of-the-art confocal microscope, a Zeiss LSM 510 Meta equipped with sophisticated software (e.g. deconvolution, image analysis, 3-D rendering) for live and fixed cell imaging. This system was acquired with the help of institutional funds from the David Geffen UCLA School of Medicine just prior to the previous competitive renewal, and since then it has been used heavily by an increasing number of CURE: DDRCC investigators. During the past funded cycle, we have also enhanced our instrumentation for calcium imaging by acquiring a Zeiss Pascal confocal microscope equipped with both short (405 nm) and visible wavelength lasers for excitation. A whole cell patch clamp recording setup is available to perform single cell electrophysiology simultaneously with confocal live cell imaging. This microscope, which has also been acquired with the help of institutional funds from the School of Medicine Dean's office, is housed at UCLA in the same building as the Zeiss 510 Meta confocal and has been extensively used by severa DDRCC investigators. Our services have also been upgraded by the addition of new imaging technologies in live cells, including quantum dots (Q-dots), photoactivatable proteins and second messengers' biosensors labeled with fluorescent tags. These significant improvements will further advance our ability to visualize macromolecules at the cellular and subcellular levels and changes in second messenger systems following cellular activation. Dr. Osvaldo Rey will join the Core personnel as Core Co-Director to supervise the new imaging methodologies that are proposed to cover the new needs of many DDRCC investigators. Finally, there will be an increased use of shared resources that are available for CURE: DDRCC investigators through arrangements made by the Core Director and existing Cores at UCLA, which are supported by the Department of Pathology and Laboratory Medicine, the Brain Research Institute and the Nanotechnology Institute. These interactions will continue to be a major effort of the Morphology and Cell Imaging Core to enhance the technical capabilities of the Core and ensure optimal utilization of shared resources within the UCLA community that includes the CURE: DDRCC community. Overall, the addition of services briefly outlined above and explained in more detail later in the body of the application reflects the evolving of the DDRCC research interests and focus, and the advances in morphological and imaging technologies. These additions will provide state-of-the-art approaches and equipment to many CURE: DDRCC investigators who are interested in elucidating fundamental normal or abnormal mechanisms in different types of cells controlling digestive functions.